Decreased Hypothalamic XXXX Receptor Expression in Type 2 @entity6 @entity1 .

@entity1 @entity6 @entity8142 @entity413 @entity5445
CONTEXT: @entity5445 ( @entity5445 ) and @entity8142 agonist treatment in type 2 @entity6 (T2DM) reduce blood @entity413 and food intake. It has been suggested that these effects are partly mediated through central @entity5445 receptors (GLP-1Rs). The rodent and nonhuman primate hypothalamus show clear @entity8142 expression. However, a detailed description of @entity8142 expression in the @entity1 hypothalamus is lacking, and it is unknown whether this expression is altered in T2DM @entity1 . OBJECTIVE: The objective of the study was to investigate the @entity8142 distribution in the @entity1 postmortem hypothalamus and to determine whether hypothalamic @entity8142 expression is altered in T2DM @entity1 . DESIGN: We investigated the distribution of @entity8142 expression throughout the @entity1 hypothalamus by means of in situ hybridization. We also performed quantifications of @entity8142 mRNA expression in two hypothalamic nuclei (ie, the paraventricular nucleus [PVN] and infundibular nucleus [IFN]), comparing @entity1 with T2DM and control subjects. RESULTS: We found that @entity8142 mRNA was expressed in a number of hypothalamic nuclei including the PVN and the IFN, both involved in the regulation of energy metabolism. We observed sporadic colocalization of the @entity8142 in the IFN with the orgexigenic neuropeptide Y, agouti-related peptide, or proopiomelanocortin transcripts. Comparison of @entity8142 mRNA in the PVN and IFN between T2DM @entity1 and control subjects revealed a decreased expression in T2DM @entity1 . CONCLUSIONS: Our studies show that @entity8142 is widely expressed throughout the @entity1 hypothalamus. The decreased expression of @entity8142 in the PVN and IFN of T2DM @entity1 may be related to the dysregulation of feeding behavior and @entity413 homeostasis in T2DM.
